These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 26839389)

  • 1. Assessing a peptidylic inhibitor-based therapeutic approach that simultaneously suppresses polyglutamine RNA- and protein-mediated toxicities in patient cells and Drosophila.
    Zhang Q; Tsoi H; Peng S; Li PP; Lau KF; Rudnicki DD; Ngo JC; Chan HY
    Dis Model Mech; 2016 Mar; 9(3):321-34. PubMed ID: 26839389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A peptidylic inhibitor for neutralizing expanded
    Zhang Q; Chen ZS; An Y; Liu H; Hou Y; Li W; Lau KF; Koon AC; Ngo JCK; Chan HYE
    RNA; 2018 Apr; 24(4):486-498. PubMed ID: 29295891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genes and pathways affected by CAG-repeat RNA-based toxicity in Drosophila.
    Shieh SY; Bonini NM
    Hum Mol Genet; 2011 Dec; 20(24):4810-21. PubMed ID: 21933837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brain-Targeting Delivery of Two Peptidylic Inhibitors for Their Combination Therapy in Transgenic Polyglutamine Disease Mice via Intranasal Administration.
    Yang M; Zhang Q; Wang Q; Sørensen KK; Boesen JT; Ma SY; Jensen KJ; Kwan KM; Ngo JCK; Chan HYE; Zuo Z
    Mol Pharm; 2018 Dec; 15(12):5781-5792. PubMed ID: 30392378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RNA toxicity is a component of ataxin-3 degeneration in Drosophila.
    Li LB; Yu Z; Teng X; Bonini NM
    Nature; 2008 Jun; 453(7198):1107-11. PubMed ID: 18449188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein transduction domain-mediated delivery of QBP1 suppresses polyglutamine-induced neurodegeneration in vivo.
    Popiel HA; Nagai Y; Fujikake N; Toda T
    Mol Ther; 2007 Feb; 15(2):303-9. PubMed ID: 17235308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CAG expansion induces nucleolar stress in polyglutamine diseases.
    Tsoi H; Lau TC; Tsang SY; Lau KF; Chan HY
    Proc Natl Acad Sci U S A; 2012 Aug; 109(33):13428-33. PubMed ID: 22847428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A brain-targeting lipidated peptide for neutralizing RNA-mediated toxicity in Polyglutamine Diseases.
    Zhang Q; Yang M; Sørensen KK; Madsen CS; Boesen JT; An Y; Peng SH; Wei Y; Wang Q; Jensen KJ; Zuo Z; Chan HYE; Ngo JCK
    Sci Rep; 2017 Sep; 7(1):12077. PubMed ID: 28935901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of polyglutamine oligomerization and neurodegeneration by the peptide inhibitor QBP1 in Drosophila.
    Nagai Y; Fujikake N; Ohno K; Higashiyama H; Popiel HA; Rahadian J; Yamaguchi M; Strittmatter WJ; Burke JR; Toda T
    Hum Mol Genet; 2003 Jun; 12(11):1253-9. PubMed ID: 12761040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RNAi for the large non-coding hsromega transcripts suppresses polyglutamine pathogenesis in Drosophila models.
    Mallik M; Lakhotia SC
    RNA Biol; 2009; 6(4):464-78. PubMed ID: 19667761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perturbation of U2AF65/NXF1-mediated RNA nuclear export enhances RNA toxicity in polyQ diseases.
    Tsoi H; Lau CK; Lau KF; Chan HY
    Hum Mol Genet; 2011 Oct; 20(19):3787-97. PubMed ID: 21725067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DnaJ-1 and karyopherin α3 suppress degeneration in a new Drosophila model of Spinocerebellar Ataxia Type 6.
    Tsou WL; Hosking RR; Burr AA; Sutton JR; Ouyang M; Du X; Gomez CM; Todi SV
    Hum Mol Genet; 2015 Aug; 24(15):4385-96. PubMed ID: 25954029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon mediated neuroinflammation in polyglutamine disease is not caused by RNA toxicity.
    Bhambri A; Pinto A; Pillai B
    Cell Death Dis; 2020 Jan; 11(1):3. PubMed ID: 31919387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delivery of the aggregate inhibitor peptide QBP1 into the mouse brain using PTDs and its therapeutic effect on polyglutamine disease mice.
    Popiel HA; Nagai Y; Fujikake N; Toda T
    Neurosci Lett; 2009 Jan; 449(2):87-92. PubMed ID: 18603372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of expanded CAG transcripts triggers nucleolar stress in Huntington's disease.
    Tsoi H; Chan HY
    Cerebellum; 2013 Jun; 12(3):310-2. PubMed ID: 23315009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Selective degradation of expanded polyglutamine proteins by their specific recognition with QBP1].
    Nagai Y; Nukina N
    Rinsho Shinkeigaku; 2011 Nov; 51(11):1108-10. PubMed ID: 22277499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expanded polyglutamine peptides alone are intrinsically cytotoxic and cause neurodegeneration in Drosophila.
    Marsh JL; Walker H; Theisen H; Zhu YZ; Fielder T; Purcell J; Thompson LM
    Hum Mol Genet; 2000 Jan; 9(1):13-25. PubMed ID: 10587574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of protein misfolding/aggregation using polyglutamine binding peptide QBP1 as a therapy for the polyglutamine diseases.
    Popiel HA; Takeuchi T; Burke JR; Strittmatter WJ; Toda T; Wada K; Nagai Y
    Neurotherapeutics; 2013 Jul; 10(3):440-6. PubMed ID: 23504628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expanded polyglutamine domain possesses nuclear export activity which modulates subcellular localization and toxicity of polyQ disease protein via exportin-1.
    Chan WM; Tsoi H; Wu CC; Wong CH; Cheng TC; Li HY; Lau KF; Shaw PC; Perrimon N; Chan HY
    Hum Mol Genet; 2011 May; 20(9):1738-50. PubMed ID: 21300695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A toxic monomeric conformer of the polyglutamine protein.
    Nagai Y; Inui T; Popiel HA; Fujikake N; Hasegawa K; Urade Y; Goto Y; Naiki H; Toda T
    Nat Struct Mol Biol; 2007 Apr; 14(4):332-40. PubMed ID: 17369839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.